Securities code: 300942 securities abbreviation: Shenzhen Bioeasy Biotechnology Co.Ltd(300942) Announcement No.: 2022-002 Shenzhen Bioeasy Biotechnology Co.Ltd(300942)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special tips:
1. Recently, the company’s share price has increased greatly, and the company’s operation and internal and external business environment have not changed significantly.
2. As of January 11, 2022, the closing price of the company was 36.70 yuan / share. According to the data released by China Securities Index Co., Ltd. on January 11, 2022, the latest rolling P / E ratio of the company is 72.73 times, and the average rolling P / E ratio of the pharmaceutical manufacturing industry in which the company is located in the latest month is 31.97 times. The P / E ratio of the company is significantly higher than that of the industry.
3. The company specially draws the attention of investors: investors should fully understand the stock market risks and the risk tips disclosed by the company, effectively improve their risk awareness, and make prudent decisions and make rational investment.
1、 Details of abnormal fluctuations in stock trading
Shenzhen Bioeasy Biotechnology Co.Ltd(300942) (hereinafter referred to as “the company”) has accumulated more than 30% deviation from the closing price increase within three consecutive trading days (January 7, 2022, January 10, 2022 and January 11, 2022). According to the relevant provisions of the special provisions on GEM trading of Shenzhen Stock Exchange, it belongs to the situation of abnormal fluctuation in stock trading.
2、 Relevant information concerned and verified by the company
According to the relevant regulations of Shenzhen Stock Exchange, the board of directors of the company verified the company, controlling shareholders and actual controllers on relevant matters by telephone or on-site inquiry. The relevant information is explained as follows: 1. The information disclosed by the company in the early stage does not need to be corrected or supplemented;
2. The company did not find that the public media recently reported information related to the company with high market attention; 3. There has been no significant change in the company’s business situation and internal and external business environment recently;
4. After verification, the company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed about the company, or major events in the planning stage;
5. During the period of stock change, the controlling shareholder and actual controller of the company do not buy or sell the company’s shares. 3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that the company does not have any undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the Shenzhen Stock Exchange GEM Listing Rules and other relevant provisions; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares and their derivatives that should be disclosed in accordance with the Shenzhen Stock Exchange GEM Listing Rules and other relevant provisions; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. As of January 11, 2022, the closing price of the company was 36.70 yuan / share. According to the data released by China Securities Index Co., Ltd. on January 11, 2022, the latest rolling P / E ratio of the company is 72.73 times. The average rolling P / E ratio of the pharmaceutical manufacturing industry in which the company is located in the latest month is 31.97 times. The P / E ratio of the company is higher than that of the industry. The company specially reminds investors to pay attention to investment risks, make rational decisions and invest prudently.
3. The company’s 2021 annual report is expected to be disclosed on April 27, 2022. Up to now, the unpublished financial information has not been provided to any third party other than the accounting firm audited by the company. Investors should pay attention to investment risks.
4. The company solemnly reminds investors that Shanghai Securities News, China Securities News, securities times, securities daily and cninfo (www.cn. Info. Com. CN.) Disclosure of information by the designated media. All information of the company shall be subject to the information published in the above designated media. Please invest rationally and pay attention to investment risks.
It is hereby announced.
Shenzhen Bioeasy Biotechnology Co.Ltd(300942) board of directors
January 11, 2022
